Shennon Biotechnologies

Finding functional cancer-targeting therapies

Shennon combines target discovery, microfluidics-driven screening, computational therapeutic design and predictive safety assessment to develop T-cell engagers. Its TCELERATOR platform measures more than 10 million single-cell interactions in one experiment, helping identify functional candidates from human tumor biology rather than relying only on sequential binder tests.

The company is developing antibody- and T-cell-receptor-based programs for solid tumors, including small-cell lung, ovarian and liver cancers. Its platform and early pipeline are in discovery and preclinical development, with oncology drug developers and clinical collaborators as the relevant partners.